NEW YORK, Nov. 10, 2019 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting demonstrating the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20...
from PR Newswire: https://ift.tt/2pOGmhC
No comments:
Post a Comment